&nbsp;

ABVD.pdf

Sep 2020

Document

ABVD-FR.pdf

Sep 2020

Regimen

ATEZBEVA

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Funding:

New Drug Funding Program

Atezolizumab with Bevacizumab (Biosimilar) - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma

New Drug Funding Program

Atezolizumab with Bevacizumab (Biosimilar) - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma

New Drug Funding Program

Atezolizumab with Bevacizumab (Biosimilar) - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma

Drugs Used:

atezolizumab,

atezolizumab (subcut),

bevacizumab

Quick Link(s):

Regimen Monograph

May 2025

Regimen

ACAL

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

acalabrutinib - For the treatment of adult patients with chronic lymphocytic leukemia (CLL), according to clinical criteria

Drugs Used:

acalabrutinib

Quick Link(s):

Regimen Monograph

Jul 2024

Regimen

ACAL+OBIN

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Drugs Used:

acalabrutinib (Unfunded),

oBINutuzumab (Unfunded)

Quick Link(s):

Regimen Monograph

Oct 2020

Regimen

ACAL(MNT)

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Drugs Used:

acalabrutinib (Unfunded)

Quick Link(s):

Regimen Monograph

Oct 2020

Document

SkinCancerPathwayAcknowledgements.pdf

Oct 2020

Skin Cancer Pathway Map

Document

SkinCancersPathwayMap.pdf

Oct 2020

Document

ST-QBPRegimenRequestStatus.pdf

Nov 2020

Regimen

ALPEFLVS

Cancer Type:

Breast

Intent: Palliative

Funding:

ODB - General Benefit

fulvestrant

Drugs Used:

fulvestrant,

alpelisib (Unfunded)